BR112013021779A2 - vacina de glicolipopeptídeo baseada em muc1 com adjuvante. - Google Patents

vacina de glicolipopeptídeo baseada em muc1 com adjuvante.

Info

Publication number
BR112013021779A2
BR112013021779A2 BR112013021779A BR112013021779A BR112013021779A2 BR 112013021779 A2 BR112013021779 A2 BR 112013021779A2 BR 112013021779 A BR112013021779 A BR 112013021779A BR 112013021779 A BR112013021779 A BR 112013021779A BR 112013021779 A2 BR112013021779 A2 BR 112013021779A2
Authority
BR
Brazil
Prior art keywords
muc1
adjuvant
glycolipopeptide
vaccine
glycolipopeptide vaccine
Prior art date
Application number
BR112013021779A
Other languages
English (en)
Portuguese (pt)
Inventor
F Hausman Diana
Millard Jeffrey
Pestano Linda
Kirkman Robert
Koppenol Sandy
Peterson Scott
Original Assignee
Oncothyreon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncothyreon Inc filed Critical Oncothyreon Inc
Publication of BR112013021779A2 publication Critical patent/BR112013021779A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001169—Tumor associated carbohydrates
    • A61K39/00117—Mucins, e.g. MUC-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
BR112013021779A 2011-02-24 2012-02-23 vacina de glicolipopeptídeo baseada em muc1 com adjuvante. BR112013021779A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161446332P 2011-02-24 2011-02-24
US201161470449P 2011-03-31 2011-03-31
PCT/US2012/026385 WO2012116225A2 (en) 2011-02-24 2012-02-23 Muc1 based glycolipopeptide vaccine with adjuvant

Publications (1)

Publication Number Publication Date
BR112013021779A2 true BR112013021779A2 (pt) 2017-09-19

Family

ID=46719120

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013021779A BR112013021779A2 (pt) 2011-02-24 2012-02-23 vacina de glicolipopeptídeo baseada em muc1 com adjuvante.

Country Status (12)

Country Link
US (3) US8889616B2 (enExample)
EP (1) EP2678005A4 (enExample)
JP (1) JP2014518841A (enExample)
KR (1) KR20140023903A (enExample)
CN (2) CN105193724A (enExample)
AR (1) AR085490A1 (enExample)
AU (1) AU2012222188A1 (enExample)
BR (1) BR112013021779A2 (enExample)
CA (1) CA2825972A1 (enExample)
MX (1) MX2013009742A (enExample)
TW (1) TWI533881B (enExample)
WO (1) WO2012116225A2 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104211796A (zh) * 2013-11-09 2014-12-17 深圳市康尔诺生物技术有限公司 胰腺癌相关肽和热休克蛋白形成的复合物及其应用
WO2015126128A1 (en) * 2014-02-18 2015-08-27 Kolon Life Science, Inc. Agent for cancer therapy
US11512289B2 (en) 2015-02-18 2022-11-29 Enlivex Therapeutics Rdo Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11304976B2 (en) 2015-02-18 2022-04-19 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11497767B2 (en) 2015-02-18 2022-11-15 Enlivex Therapeutics R&D Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11000548B2 (en) 2015-02-18 2021-05-11 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11596652B2 (en) 2015-02-18 2023-03-07 Enlivex Therapeutics R&D Ltd Early apoptotic cells for use in treating sepsis
US11318163B2 (en) 2015-02-18 2022-05-03 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
JP6803339B2 (ja) 2015-04-21 2020-12-23 エンリヴェックス セラピューティクス リミテッド 治療用のプールされた血液アポトーシス細胞調製物及びそれらの使用
JP6884155B2 (ja) 2016-02-18 2021-06-09 エンリヴェックス セラピューティクス リミテッド 癌治療のための併用免疫療法及びサイトカイン制御療法
CN106620682A (zh) * 2017-01-19 2017-05-10 华中师范大学 一种脂质体疫苗制剂及其用途和生产IgG抗体的方法
WO2019035605A2 (ko) * 2017-08-16 2019-02-21 주식회사 차백신연구소 리포펩티드가 삽입된 리포좀을 유효성분으로 포함하는 백신 아쥬반트 및 이의 용도
KR102098097B1 (ko) 2017-08-16 2020-05-26 주식회사 차백신연구소 리포펩티드가 삽입된 리포좀을 유효성분으로 포함하는 백신 아쥬반트 및 이의 용도
CN109513002B (zh) * 2017-09-19 2024-02-20 台北医学大学 缓解发炎的tn疫苗及方法
CN112516300A (zh) * 2019-12-04 2021-03-19 华中师范大学 一种抗肿瘤疫苗分子及其制备方法和应用
CN111760020B (zh) * 2020-05-18 2023-05-26 广州中医药大学(广州中医药研究院) 一种缀合物及其制备方法和应用
CN111760021B (zh) * 2020-05-18 2023-06-16 广州中医药大学(广州中医药研究院) 一种含有α-半乳糖神经酰胺类似物与糖抗原的缀合物及其制备方法和应用

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB699080A (en) 1950-05-31 1953-10-28 Ici Ltd Production of new esters of ortho-phosphoric acid and salts thereof
US3930024A (en) 1969-09-02 1975-12-30 Parke Davis & Co Pharmaceutical compositions and methods
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US5019383A (en) 1981-01-09 1991-05-28 New York Blood Center, Inc. Fatty acid carriers for synthetic peptides
DE3127503A1 (de) 1981-07-11 1983-02-17 Boehringer Mannheim Gmbh, 6800 Mannheim Neue phospholipide, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
US4464383A (en) 1981-11-24 1984-08-07 Itaru Yamamoto Immunomodulator containing trithiazole pentamethine cyanine derivative
ZA831547B (en) 1982-03-15 1984-10-31 New York Blood Center Inc Fatty acid carriers for synthetic vaccines
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
DE3476770D1 (en) 1983-04-11 1989-03-23 Meito Sangyo Kk Production of primary or secondary alcohol derivatives of phospholipids by the enzymatic technique
US6090406A (en) 1984-04-12 2000-07-18 The Liposome Company, Inc. Potentiation of immune responses with liposomal adjuvants
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
GR860379B (en) 1985-02-22 1986-06-11 Akzo Nv Novel disaccharide and trisaccharide derivatives of the lipid a type
WO1986005687A1 (en) 1985-04-03 1986-10-09 Wisconsin Alumni Research Foundation Method of preventing diseases caused by gram-negative endotoxin in mammals
US5837249A (en) 1985-04-19 1998-11-17 The Wistar Institute Method for generating an immunogenic T cell response protective against a virus
ATE72123T1 (de) 1985-04-19 1992-02-15 Wistar Inst Impfstoff fuer die erzeugung einer gegen ein virus schuetzenden immunogenen t-zellen-antwort.
IT1213029B (it) 1986-01-30 1989-12-07 Bracco Ind Chimica Spa Chelati di ioni metallici paramagnetici.
JPS63139186A (ja) 1986-11-29 1988-06-10 Hidetoshi Tsuchida 三本鎖型リン脂質化合物およびその製造方法
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US4868155A (en) 1987-10-05 1989-09-19 Merck & Co., Inc. Dipeptidyl 4-0-,6-0-acyl-2-amino-2-deoxy-D-glucose compositions and methods of use in AIDS-immunocompromised human hosts
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5041427A (en) 1989-07-21 1991-08-20 Wisconsin Alumni Research Foundation Lipid A derivatives
JPH0655749B2 (ja) 1989-09-20 1994-07-27 日本たばこ産業株式会社 リピッドａ単糖類縁体
US5871746A (en) 1990-12-18 1999-02-16 Institut National De La Sainte Et De La Recherche Medicale (Inserm) Cytotoxic T lymphocyte-inducing lipopeptides and use as vaccines
FR2670787B1 (fr) 1990-12-18 1995-06-23 Pasteur Institut Lipopeptides inducteurs des lymphocytes t cytotoxiques et utilisation comme vaccins.
US5993823A (en) 1990-12-18 1999-11-30 Institut Pasteur De Lille Cytotoxic T lymphocyte-inducing lipopeptides and methods of use
ES2044781B1 (es) 1992-04-14 1994-10-01 Menarini Lab Procedimiento para la preparacion de nuevas amidas con accion inhibidora de la fosfolipasa a2
US5580563A (en) 1992-05-01 1996-12-03 Tam; James P. Multiple antigen peptide system having adjuvant properties, vaccines prepared therefrom and methods of use thereof
FR2702306B1 (fr) 1993-03-05 1995-04-14 Alcatel Nv Procédé d'auto-alignement d'un contact métallique sur un substrat de matériau semi-conducteur.
IT1264690B1 (it) 1993-07-08 1996-10-04 Bracco Spa Compositi oligomeri iodurati e composizioni diagnostiche contenenti gli stessi
US5744144A (en) 1993-07-30 1998-04-28 University Of Pittsburgh University Patent Committee Policy And Procedures Synthetic multiple tandem repeat mucin and mucin-like peptides, and uses thereof
DE4408248A1 (de) 1994-03-11 1995-09-14 Hoechst Ag Physiologisch verträgliche und physiologisch abbaubare Kohlenhydrat-Mimetika, ein Verfahren zur Herstellung und ihre Verwendung
AU2247095A (en) 1994-04-12 1995-10-30 Biomira Inc. Cellular immune response-specific antigens and uses therefor
WO1995029927A2 (en) 1994-05-02 1995-11-09 Biomira, Inc. Process for preparation of glycosides of tumor-associated carbohydrate antigens
AU6260796A (en) 1995-06-07 1996-12-30 National Jewish Center For Immunology And Respiratory Medicine Isolated formylated bacterial peptides, nucleic acid molecul es and uses thereof
AUPN568095A0 (en) 1995-09-27 1995-10-26 Austin Research Institute, The Anti-Galalpha(1,3)Gal antibody binding peptides
US5840839A (en) 1996-02-09 1998-11-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein
WO1997034921A1 (en) 1996-03-20 1997-09-25 Sloan-Kettering Institute For Cancer Research Conjugated mucin peptide vaccines
WO1997038010A2 (en) 1996-04-11 1997-10-16 The University Of British Columbia Fusogenic liposomes
US5910306A (en) 1996-11-14 1999-06-08 The United States Of America As Represented By The Secretary Of The Army Transdermal delivery system for antigen
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
DE69839443D1 (de) 1997-05-08 2008-06-19 Biomira Inc Verfahren zur gewinnung von aktivierten t-zellen und mit antigen inkubierten antigenpräsentierenden zellen
US6764840B2 (en) 1997-05-08 2004-07-20 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
FR2774687B1 (fr) 1998-02-06 2002-03-22 Inst Nat Sante Rech Med Lipopeptides contenant un fragment de l'interferon gamma, et leur utilisation dans des compositions pharmaceutiques
EP1056472A2 (en) * 1998-02-13 2000-12-06 BASTERT, Gunter, Prof.Dr.med.Dr.h.c. Specific antibodies against mammary tumor-associated mucin, method for production and use
US6043390A (en) 1998-04-03 2000-03-28 The Regents Of The University Of California Pentaerythritol lipid derivatives and nucleic-acid complexes
FR2776926B1 (fr) 1998-04-07 2003-10-24 Inst Nat Sante Rech Med Lipopeptides inducteurs de cytotoxicite t lymphocytaire portant au moins un epitope t auxiliaire, et leurs utilisations pour la vaccination
US20020051813A1 (en) 1999-01-15 2002-05-02 Lawrence Boni Lipomatrix preparation
US7147850B2 (en) 1999-08-18 2006-12-12 Altarex Medical Corp. Therapeutic binding agents against MUC-1 antigen and methods for their use
JP2003519096A (ja) 1999-08-18 2003-06-17 アルタレックス コーポレーション Ｍｕｃ−１抗原に対する治療用抗体およびその使用方法
WO2001018035A2 (en) 1999-09-08 2001-03-15 Transgene S.A. Muc-1 derived peptides
US7491707B1 (en) 1999-11-15 2009-02-17 Biomira, Inc. Synthetic lipid-a-analogs and uses thereof
US6699846B2 (en) 2000-03-17 2004-03-02 Corixa Corporation Mono- and disaccharides for the treatment of nitric oxide related disorders
CA2404327A1 (en) 2000-03-24 2001-09-27 Biomira, Inc. Lipopeptide adjuvants
ES2164013B1 (es) 2000-04-14 2003-06-16 Consejo Superior Investigacion Glicosidos de n-acetil-6-o-(2,2-bis(hidroximetil)-3-hidroxipropil)-d-glucosamina, procedimiento de obtencion y uso en el tratamiento de tumores cerebrales.
EP1182210A1 (en) 2000-08-17 2002-02-27 BASTERT, Gunter, Prof.Dr.med.Dr.h.c. Epitopes of tumor-associated MUC1 antigen
WO2002022685A2 (en) * 2000-09-11 2002-03-21 Kufe Donald W Muc1 extracellular domain and cancer treatment compositions and methods derived therefrom
DE60134265D1 (de) 2000-12-01 2008-07-10 Biomira Inc Herstellung grosser liposome durch infusion in peg
ES2424131T3 (es) 2001-03-27 2013-09-27 Oncothyreon Inc. Vacuna para modular respuestas inmunitarias entre T1 y T2
AU2003203079B9 (en) 2002-02-04 2009-01-15 Oncothyreon Inc. Immunostimulatory, covalently lipidated oligonucleotides
EP1572918B1 (en) 2002-04-15 2011-10-19 Oncothyreon Inc. Synthetic glyco-lipo-peptides as vaccines
JP5014573B2 (ja) 2002-05-09 2012-08-29 オンコサイレオン インコーポレーテッド 脂質ａおよび他の炭水化物リガンド類似体
GB0212046D0 (en) * 2002-05-24 2002-07-03 Glaxo Group Ltd Vaccines
US20030235610A1 (en) 2002-06-21 2003-12-25 Piedmont Pharmaceuticals, Llc Liposomes containing biologically active compounds
US9198645B2 (en) 2003-11-26 2015-12-01 The United States of America, as represented by the Secretary of Commerce of The National Institute of Standards and Technology Controlled vesicle self-assembly in continuous two phase flow microfluidic channels
TW201204410A (en) 2004-04-01 2012-02-01 Oncothyreon Inc Mucinous glycoprotein (MUC-1) vaccine
PT2366400E (pt) 2005-06-28 2016-02-02 Oncothyreon Inc Método de tratamento de doentes com uma vacina à base de glicoproteína mucinosa (muc-1)
JP5126874B2 (ja) 2007-05-21 2013-01-23 国立大学法人神戸大学 リポソーム製剤の製造方法
MX2011006562A (es) 2008-12-17 2011-09-27 Oncothyreon Inc Metodo para elaborar liposomas pequeños.

Also Published As

Publication number Publication date
WO2012116225A9 (en) 2013-06-27
US8889616B2 (en) 2014-11-18
TW201309326A (zh) 2013-03-01
US20120282329A1 (en) 2012-11-08
EP2678005A2 (en) 2014-01-01
AR085490A1 (es) 2013-10-09
CA2825972A1 (en) 2012-08-30
CN103781469A (zh) 2014-05-07
US8329639B2 (en) 2012-12-11
KR20140023903A (ko) 2014-02-27
JP2014518841A (ja) 2014-08-07
CN103781469B (zh) 2015-09-16
US20150064240A1 (en) 2015-03-05
TWI533881B (zh) 2016-05-21
WO2012116225A3 (en) 2014-04-24
US20120219617A1 (en) 2012-08-30
MX2013009742A (es) 2014-01-31
WO2012116225A2 (en) 2012-08-30
CN105193724A (zh) 2015-12-30
AU2012222188A1 (en) 2013-08-15
EP2678005A4 (en) 2015-06-10

Similar Documents

Publication Publication Date Title
PL4223311T3 (pl) Zindywidualizowane szczepionki przeciwnowotworowe
BR112014033077A2 (pt) combinação de vacina.
DK3246416T3 (da) Sikkert sekventeringssystem
BR112013024256A2 (pt) veículo.
ITRM20120030A1 (it) Apparato di controllo della posizione.
EP2678005A4 (en) GLUCOLOPOPEPTIDE MUC1-BASED VACCINE WITH AN ADJUVANS
EP2754059A4 (en) ENCODED CLIENT FAILURE
ITMI20120696A1 (it) Ventilconvettore.
BR112014005756A2 (pt) vacina
EP2791653A4 (en) PROCESS FOR OPTIMIZED SCATTEROMETRY
BR112013023601A2 (pt) unidade de bobina.
BR112014000890A2 (pt) microorganismo
UA23273S (uk) Келих
DK2686011T3 (da) Ipn-vaccine
EP2667891A4 (en) COMBINATION VACCINES
FR2972076B1 (fr) Actionneur magnetothermique.
FR2978994B1 (fr) .
EP2756697A4 (en) AUTHENTICATION MECHANISM
FR2973145B1 (fr) Atlas visuo-tactile.
ES2397885B1 (es) Derivados de colismicina.
FR2980994B1 (fr) Prehenseur multi-plaquettes.
HUE038117T2 (hu) Hevítõberendezés
FI9450U1 (fi) Hokkijärjestelmä
FR2980731B1 (fr) Fendeuse de buches
ES1074780Y (es) Columna-luminaria.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2450 DE 19-12-2017 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.